Key Highlights

  • Third-quarter 2026 Revenue was $31.944 million, against $34.993 million in the third quarter of 2025.
  • Net loss was $7.173 million, or $0.10 per diluted share, against $9.512 million, or $0.15 per share, a year earlier.
  • Adjusted EBITDA was about $0.4 million, against $3 million in the prior-year quarter.
  • Full-year 2026 revenue is now expected at $144 million to $146 million, from $151 million to $157 million.
  • Gross Margin was roughly 60% of revenue, compared with 57.5% a year earlier.

AirSculpt Technologies (NASDAQ:AIRS), a provider of body contouring procedures, reported third-quarter 2026 results before the market opened on Friday. Revenue was $31.944 million, compared with $34.993 million a year earlier, a decrease of 8.7%. Market estimates had pointed to revenue of $34.33 million.

On a same-center basis, excluding London, revenue declined about 7.5%, reflecting a 9.6% decline in case Volume that was partly offset by a 2.3% increase in average selling price. Average selling price was approximately $12,900. Net loss was $7.173 million, or $0.10 per diluted share, compared with a net loss of $9.512 million, or $0.15 per share, a year earlier.

Margins Improve While Adjusted EBITDA Declines

Gross margin expanded to roughly 60% of revenue from 57.5% in the prior-year quarter. Adjusted EBITDA was approximately $0.4 million, or roughly 1.2% of revenue, compared with $3 million, or 8.7% of revenue, a year earlier. The company said the decline primarily reflects lower revenue and reduced operating leverage, partly offset by cost discipline.

For the first nine months of 2026, revenue was $114.233 million, against $118.376 million in the same period of 2025. Net loss for the nine months was $10.682 million, compared with $12.950 million.

Full-Year Revenue and Adjusted EBITDA Outlook Reduced

AirSculpt now expects 2026 revenue of $144 million to $146 million, compared with a previous outlook of $151 million to $157 million. It expects adjusted EBITDA of $9 million to $10 million, against a prior range of $12 million to $14 million.

Management said the outlook assumes the challenges seen in the third quarter continue through the fourth quarter, which it described as the prudent approach.

GLP-1 Patients and the Term Loan Refinancing

The company said GLP-1-related procedures represented nearly 10% of total cases in the quarter and that it believes it is in the early stages of GLP-1-related aesthetic procedure growth. Patient conversion held steady.

AirSculpt also announced the refinancing of its term loan, extending the Maturity to 2031. It ended the quarter with roughly $15 million in cash and about $5 million of availability.

Fourth-Quarter Trends and Loan Extension Frame the Next Update

The revised outlook rests on case volume trends holding at third-quarter levels through year-end. The extended loan maturity is the Balance Sheet item management highlighted alongside the results.